Insulet Corporation (PODD)
| Market Cap | 10.96B |
| Revenue (ttm) | 2.90B |
| Net Income (ttm) | 302.80M |
| Shares Out | 69.26M |
| EPS (ttm) | 4.29 |
| PE Ratio | 36.89 |
| Forward PE | 23.65 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,779,076 |
| Open | 154.45 |
| Previous Close | 153.82 |
| Day's Range | 154.45 - 160.92 |
| 52-Week Range | 138.79 - 354.88 |
| Beta | 1.12 |
| Analysts | Strong Buy |
| Price Target | 240.25 (+53.19%) |
| Earnings Date | Aug 6, 2026 |
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controll... [Read more]
Financial Performance
In 2025, Insulet's revenue was $2.71 billion, an increase of 30.73% compared to the previous year's $2.07 billion. Earnings were $247.10 million, a decrease of -40.93%.
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for PODD stock is "Strong Buy." The 12-month stock price target is $240.25, which is an increase of 53.19% from the latest price.
News
Insulet appoints Mazelsky to its Board of Directors
Insulet (PODD) Corporation announced the appointment of Jonathan Mazelsky to the Company’s Board of Directors, effective July 1, 2026. Mazelsky joins the Board as an independent director. Published fi...
Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...
Insulet initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Kieran Ryan initiated coverage of Insulet (PODD) with a Buy rating and $190 price target The firm acknowledges potential headwinds over time from competition in tubeless and…
Insulet initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of Insulet (PODD) with a Buy rating and $190 price target
Insulet price target lowered to $219 from $250 at Truist
Truist lowered the firm’s price target on Insulet (PODD) to $219 from $250 and keeps a Buy rating on the shares after hosting an NDR meeting with Insulet’s management, including…
Insulet price target lowered to $216 from $263 at Raymond James
Raymond James lowered the firm’s price target on Insulet (PODD) to $216 from $263 and keeps an Outperform rating on the shares. The firm noted that there continues to be…
Insulet announces new results on tubeless AID systems
Insulet (PODD) announced new clinical results highlighting the “next breakthroughs” in tubeless Automated Insulin Delivery, AID, systems. The data and growing body of evidence not only confirm the imp...
CDRH issues Early Alert about pump issue from Insulet
The FDA is aware that Insulet (PODD) has issued a letter to affected customers recommending certain Omnipod Pods be removed from where they are used or sold, the agency noted.
Insulet announces planned activities during ADA Scientific Sessions
Insulet (PODD) announced its planned activities during the American Diabetes Association, ADA, 86th Scientific Sessions, taking place June 5 – 8, 2026 in New Orleans. Insulet’s presence at ADA highlig...
Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions
ACTON, Mass.--(BUSINESS WIRE)--Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at ADA.
Insulet Transcript: 46th Annual William Blair Growth Stock Conference
Strong financial performance and innovation drive growth, with new algorithm and product launches expanding market reach. Quality issues addressed with corrective actions, and a robust pipeline supports confidence in 20% annual revenue growth through 2028.
Insulet Slides: 46th Annual William Blair Growth Stock Conference
Insulet has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Insulet announces U.S. rollout of enhanced Omnipod 5 algorithm
Insulet (PODD) Corporation announced the U.S. rollout of new algorithm enhancements for the Omnipod 5 Automated Insulin Delivery, AID, System. The updates follow FDA 510(k) clearance in December 2025....
Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor
ACTON, Mass.--(BUSINESS WIRE)--Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor.
Insulet court victory over EOFlow reversed on appeal
The U.S. Federal Circuit Court of Appeals ruled that Insulet (PODD) cannot collect a $59.4M insulin pump trade secrets award from EOFlow because it filed its lawsuit too late. “On…
US court overturns Insulet's $452 mln insulin-pump trade secret verdict against EOFlow
A U.S. appeals court on Thursday overturned a $452 million verdict that medical device maker Insulet won against Korean rival EOFlow for allegedly stealing trade secrets related to its insulin-p...
Insulet price target lowered to $165 from $175 at Citi
Citi lowered the firm’s price target on Insulet (PODD) to $165 from $175 and keeps a Neutral rating on the shares. The firm updated models in the medical technology space…
Insulet to Participate in William Blair 46th Annual Growth Stock Conference
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will prese...
Insulet price target lowered to $205 from $237 at Goldman Sachs
Goldman Sachs analyst David Roman lowered the firm’s price target on Insulet (PODD) to $205 from $237 and keeps a Buy rating on the shares. MedTech has experienced one of…
Insulet price target lowered to $235 from $260 at BTIG
BTIG lowered the firm’s price target on Insulet (PODD) to $235 from $260 and keeps a Buy rating on the shares after the company announced a voluntary medical device correction…
Insulet flags dosing defect in some Omnipod devices, sees up to $50 million cost
Insulet said on Tuesday it is carrying out a voluntary correction of certain insulin pump pods across its Omnipod product lines after identifying a manufacturing issue that could result in patients ...
Insulet initiates voluntary medical device correction for certain Omnipod lots
Insulet (PODD) Corporation announced a voluntary Medical Device Correction for specific lots of Omnipod 5, Omnipod DASH, and Omnipod Insulin Management System Pods due to a manufacturing issue, identi...
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation, Inc. (NASDAQ: PODD) (“Insulet” or the “Company”) today announced a voluntary Medical Device Correction for specific lots of Omnipod® 5, Omnipod DASH...
Insulet Transcript: AGM 2026
The meeting highlighted a decade of strong revenue growth, global expansion, and innovation in diabetes care. All board nominees were elected, executive compensation was approved, and auditors ratified. Leadership addressed shareholder concerns about stock performance and future competition.